This focused issue on “HCC in the Era of DAAs” is edited by Dr. Gamal Shiha, from Faculty of Medicine, Mansoura University, Dakahlia, Egypt.
This focused issue is designed to discuss hepatocellular carcinoma (HCC) in the era of direct-acting antivirals (DAA). Complex and controversial issues that are on the minds of many will be addressed by yourself. This focused issue reviews recent literature, provides expert insight into current practice, and also identifies future directions.
Gamal Shiha, MBBCH, MSc, MD, PhD
GI and liver Unit, Specialized Medical Hospital, Faculty of Medicine, Mansoura University, Dakahlia, Egypt
Dr. Shiha is Professor of Internal Medicine, and the Head of G.I & Liver Unit, Mansoura University. He is the founder and head of the Association of Liver Patients Care (ALPC) & the Egyptian Liver Research Institute and Hospital (ELRIAH).
For his life time outstanding achievements & contributions to medicine, he is a member of various scientific societies; the Egyptian Gastrointestinal Endoscopic Society, European Association for the Study of the liver (EASL), American Association for the Study of Liver Diseases (AASLD), and Asian Pacific Association for the Study of Liver Diseases (APASL).
Focused issue outline:
The complete outline of this focused issue is listed below:
- Introduction to the focused issue
- Mechanisms of hepatitis C virus-induced hepatocellular carcinoma
- Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients
- Tumor behaviour of HCC following DAAs
- Simple Score for HCC stratification in CHC patients who achieved SVR following DAA therapy
- Direct acting antivirals and HCC reccurence
- Survillence of HCC following micro and macro elimination of HCV